M

María Luisa Maestro de las Casas

Hospital Clínico San Carlos

ORCID: 0000-0001-6959-1556

Publishes on Cancer Cells and Metastasis, COVID-19 Clinical Research Studies, COVID-19 epidemiological studies. 67 papers and 768 citations.

67Publications
768Total Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

The Role of Zoos and Aquariums in a Changing World
Rafael Miranda, Nora Escribano, María Luisa Maestro de las Casas et al.|Annual Review of Animal Biosciences|2022
Cited by 51Open Access

Zoos and aquariums have evolved significantly. From their origins as enclosures for the mere entertainment of the public, these institutions have undertaken new functions responding to the biodiversity crisis and social demands. Modern zoos and aquariums have the opportunity to educate people, contribute to species conservation, and produce animal-related research. However, there is increasing criticism toward the outcomes of their actions and the holding of species in their facilities. This review offers an integrated analysis of the state of knowledge about the role that zoos and aquariums play today. It describes their performance regarding their conservation, education, and research functions, highlighting general patterns and offering future perspectives. It identifies some challenges common to all these institutions, concluding that the way they keep up with the ever-growing social and environmental expectations will be decisive hereafter.

Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis
E. Redondo-González, Leandro Nunes de Castro, Jesús Moreno Sierra et al.|BioMed Research International|2015
Cited by 46Open Access

Bladder cancer occurs in the epithelial lining of the urinary bladder and is amongst the most common types of cancer in humans, killing thousands of people a year. This paper is based on the hypothesis that the use of clinical and histopathological data together with information about the concentration of various molecular markers in patients is useful for the prediction of outcomes and the design of treatments of nonmuscle invasive bladder carcinoma (NMIBC). A population of 45 patients with a new diagnosis of NMIBC was selected. Patients with benign prostatic hyperplasia (BPH), muscle invasive bladder carcinoma (MIBC), carcinoma in situ (CIS), and NMIBC recurrent tumors were not included due to their different clinical behavior. Clinical history was obtained by means of anamnesis and physical examination, and preoperative imaging and urine cytology were carried out for all patients. Then, patients underwent conventional transurethral resection (TURBT) and some proteomic analyses quantified the biomarkers (p53, neu, and EGFR). A postoperative follow-up was performed to detect relapse and progression. Clusterings were performed to find groups with clinical, molecular markers, histopathological prognostic factors, and statistics about recurrence, progression, and overall survival of patients with NMIBC. Four groups were found according to tumor sizes, risk of relapse or progression, and biological behavior. Outlier patients were also detected and categorized according to their clinical characters and biological behavior.